• Russell 2000 (June 2016)

Merrimack Pharmaceuticals Inc

MERRIMACK
1 Broadway FL 14
Cambridge, MA, 02142-1187  United States
(617) 441-1000
Company Type: Corporation Independent

Merrimack Pharmaceuticals takes a technological approach to fighting cancer. A biopharmaceutical company, Merrimack develops oncology drugs using its proprietary Network Biology technology, which combines biological data and computer-based modeling to discover and develop candidates. In 2015, it received US approval and Taiwan approval of ONIVYDE for the treatment of pancreatic cancer, but it sold that drug to Ipsen in 2017. The firm then owned three key programs, but two of those failed in mid-stage testing. A year after slashing its workforce by 80%, it announced plans to cut another 60% of its staff in 2018. Merrimack traces its roots back to the early 1990s.

Try D&B Hoovers Free

Competitor Profiles

See detailed profiles for insights and prospects on this company's top competitors.

For Your Call

Essential information for a successful call

  • ASSETS (MIL USD) 89
  • TICKER SYMBOL MACK
  • Incorporated 1993
  • MARKET VALUE (MIL USD) 62.3
  • FISCAL YEAR END DEC
  • EMPLOYEE GROWTH % -62.5%

Get in Touch with 12 Contacts

A D&B Hoovers Subscription is your foot in the door to Merrimack Pharmaceuticals Inc contact information.
  • Gary L. Crocker
    Chairman
  • Jean M. Franchi
    CFO
  • Richard Peters
    President and CEO
See full contact details
Start Your Free Trial

Get full access to D&B Hoovers

With a Hoovers subscription you can get a comprehensive view of Merrimack Pharmaceuticals Inc

Merrimack Pharmaceuticals Inc

12
Contacts
Reach the right people with access to detailed contact information.
9
Close Industry Peers
See similar companies for insight and prospecting.
Start Live ChatChat

*Required Fields

FREE Alerts to Changes in Your D&B® Credit Scores!* Sign Up. Get CreditSignal® for FREE!*
Try D&B Credit FREE for 30 Days! Get Started. Try D&B Credit FREE for 30 Days